# Phase 2 Study of Safety, Efficacy, and Pharmacokinetics of Higher Doses of Daptomycin and Vancomycin in MRSA Bacteremia

> **NCT00695903** · PHASE2 · TERMINATED · sponsor: **Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)** · enrollment: 38 (actual)

## Conditions studied

- Endocarditis, Bacterial
- Infective Endocarditis

## Interventions

- **DRUG:** daptomycin
- **DRUG:** vancomycin

## Key facts

- **NCT ID:** NCT00695903
- **Lead sponsor:** Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-09-17
- **Primary completion:** 2010-08-24
- **Final completion:** 2010-10-01
- **Target enrollment:** 38 (ACTUAL)
- **Why stopped:** terminated due to lack of enrollment
- **Last updated:** 2018-12-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00695903

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00695903, "Phase 2 Study of Safety, Efficacy, and Pharmacokinetics of Higher Doses of Daptomycin and Vancomycin in MRSA Bacteremia". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT00695903. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*